NovaBay Pharmaceuticals Files S-1/A Amendment
Ticker: NBY · Form: S-1/A · Filed: Jul 25, 2024 · CIK: 1389545
Sentiment: neutral
Topics: sec-filing, s-1a, pharmaceuticals
Related Tickers: NBY
TL;DR
NovaBay Pharma filed an S-1/A amendment, likely for a stock offering. Keep an eye on details.
AI Summary
NovaBay Pharmaceuticals, Inc. filed an S-1/A amendment on July 24, 2024, for a registration statement under the Securities Act of 1933. The filing, with registration number 333-280423, indicates an amendment to a previous filing. The company is incorporated in Delaware and its principal executive offices are located at 2000 Powell Street, Suite 1150, Emeryville, CA 94608.
Why It Matters
This S-1/A filing signifies an update to NovaBay Pharmaceuticals' registration statement, which is a crucial step in the process of offering securities to the public.
Risk Assessment
Risk Level: medium — S-1/A filings often relate to stock offerings, which can be volatile and carry inherent risks for investors.
Key Numbers
- 333-280423 — Registration Number (Identifies this specific SEC filing and potential securities offering.)
Key Players & Entities
- NovaBay Pharmaceuticals, Inc. (company) — Registrant
- 333-280423 (dollar_amount) — Registration Number
- July 24, 2024 (date) — Filing Date
- Justin M. Hall (person) — Chief Executive Officer and General Counsel
- Squire Patton Boggs (US) LLP (company) — Legal Counsel
FAQ
What is the purpose of this S-1/A filing?
This is an amendment to a Form S-1 registration statement, indicating updates or changes to the company's initial filing for a securities offering.
When was this amendment filed?
The amendment was filed with the SEC on July 24, 2024.
What is the company's principal executive office address?
The company's principal executive offices are located at 2000 Powell Street, Suite 1150, Emeryville, CA 94608.
Who is the CEO and General Counsel of NovaBay Pharmaceuticals?
Justin M. Hall serves as the Chief Executive Officer and General Counsel for NovaBay Pharmaceuticals, Inc.
What is the registration number associated with this filing?
The registration number for this filing is 333-280423.
Filing Stats: 4,656 words · 19 min read · ~16 pages · Grade level 16.3 · Accepted 2024-07-24 20:49:05
Key Financial Figures
- $0 — 2 shares of our common stock, par value $0.01, or common stock, and up to 1,643,19
- $2.13 — o purchase one share of common stock is $2.13. Each Series F-1 warrant will have an e
Filing Documents
- nby20240724c_s1a.htm (S-1/A) — 617KB
- ex_702555.htm (EX-1) — 247KB
- ex_702896.htm (EX-4) — 125KB
- ex_702897.htm (EX-4) — 120KB
- ex_702556.htm (EX-4) — 116KB
- ex_702557.htm (EX-4) — 131KB
- ex_702558.htm (EX-5) — 16KB
- ex_702559.htm (EX-23) — 3KB
- ex_702560.htm (EX-FILING FEES) — 55KB
- logo01.jpg (GRAPHIC) — 9KB
- a01.jpg (GRAPHIC) — 40KB
- a02.jpg (GRAPHIC) — 23KB
- a03.jpg (GRAPHIC) — 19KB
- logo02.jpg (GRAPHIC) — 11KB
- ex_702558img001.jpg (GRAPHIC) — 4KB
- 0001437749-24-023391.txt ( ) — 1576KB
Risk Factors
Risk Factors 13 Special Note Regarding Forward-Looking Statements 25
Use of Proceeds
Use of Proceeds 26 Dividend Policy 27
Dilution
Dilution 28 Principal Stockholders 30
Description of Capital Stock
Description of Capital Stock 31
Description of Securities We Are Offering
Description of Securities We Are Offering 35
Underwriting
Underwriting 39 Legal Matters 42 Experts 42 Where You Can Find More Information 42 Incorporation of Certain Documents by Reference 42 ABOUT THIS PROSPECTUS This registration statement filed with the Securities and Exchange Commission, or the SEC, includes exhibits and documents incorporated by reference that provide more detail on the matters discussed in this prospectus. You should read this prospectus, the related exhibits filed with the SEC and the documents incorporated by reference herein before making your investment decision. You should rely only on the information that we have included or incorporated by reference in this prospectus and any related free writing prospectus that we may authorize to be provided to you. We have not, and the underwriter has not, authorized anyone to provide you with information or to make any representation that is in addition to, or different from, that contained or incorporated by reference in this prospectus or contained in any permitted free writing prospectuses we have authorized for use in connection with this offering. If anyone provides you with different or inconsistent information, you should not rely on it as having been authorized by us in making a decision about whether to invest in the securities. We take no responsibility for, and cannot provide any assurance as to the reliability of, any other information that others may provide to you. The information contained in this prospectus, any related free writing prospectus and the documents incorporated by reference herein are accurate only as of their respective dates, regardless of the time of delivery of any such document or the time of any sale of the securities. Our business, assets, financial condition, results of operations and prospects may have changed since those dates. Therefore, you should not assume that the information contained in this prospectus or any related free writing prospectus is accurate on any date subsequent to the date set forth